Learn more
Stem cells
Products offered through the platform are not approved by the U.S. Food and Drug Administration. They are experimental, and potential risks and benefits should be discussed with a physician.
What a stem cell is, what the cells usually called mesenchymal stem cells are, how they are defined, and how much is and is not known about them. This page describes biology. It does not describe a treatment, or what any treatment might do.
What a stem cell is
Stem cells can renew themselves, and can develop into many different cell types during early life and growth.1
Researchers group them into categories. Pluripotent stem cells, which include embryonic stem cells and induced pluripotent stem cells made in a laboratory, can give rise to all of the cells of the adult body. Adult stem cells are found in a particular tissue or organ, and give rise to the specialised cell types of that tissue or organ.1 A cell that can give rise to several cell types, but not to all of them, is called multipotent.2
- A pluripotent cell can give rise to all the tissues of an organism.2
- Cells of all three germ layers: ectoderm, mesoderm and endoderm.15
- A mesenchymal stromal cell, grown on plastic in a dish.3
- To meet the international definition, these cells must be able to become bone-forming cells, fat cells and cartilage cells in the dish.3
Mesenchymal stromal cells
Mesenchymal stromal cells, or MSCs, are fibroblast-like cells that attach to plastic in culture, whatever tissue they came from.4 Bone marrow and the fat-derived stromal vascular fraction are the most common and longest-used sources, and umbilical cord tissue and placenta are used as well.8
The history goes back to 1970, when Friedenstein and colleagues grew colonies of fibroblast-like cells from guinea pig bone marrow and spleen.7 Friedenstein was the first to culture bone-forming cells this way.8 The isolation and growth of human bone marrow MSCs was reported in 1992,8 and in 1999 a study in Science showed that single cells from human marrow, grown into colonies, kept the ability to form several mesenchymal tissues.9
How they are defined
In 2006 the International Society for Cellular Therapy set out the minimum a cell population must show to be called an MSC.3
-
They stick to plasticIn standard culture, the cells must attach to the plastic surface of the dish.3
-
They carry some markers and lack othersThey must carry CD105, CD73 and CD90 on their surface, and lack CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR.3
-
They can become three cell types in a dishThey must be able to become osteoblasts, adipocytes and chondroblasts (bone-forming, fat and cartilage cells) in the laboratory.3
Its authors expected the criteria would "probably require modification as new knowledge unfolds".3 Thirteen years later, a group from four scientific societies called them "a rudimentary definition that serves more to eliminate cells that are not MSCs rather than to define cells that are MSCs".10
Stem, or stromal?
The "S" in MSC has meant different things. In 2005 the International Society for Cellular Therapy wrote that the mixed population of cells usually studied does not meet accepted criteria for stem cell activity, making the name "mesenchymal stem cell" "scientifically inaccurate and potentially misleading to the lay public". It recommended "multipotent mesenchymal stromal cells", keeping "stem" for cells that meet specified stem cell criteria.4
In 2019 the MSC committee of the International Society for Cell & Gene Therapy restated the position: the cells should be described with the tissue they came from, and called stromal unless there is rigorous evidence of "stemness", from both the dish and living organisms.6
In 2017 Caplan went further and proposed renaming them "Medicinal Signaling Cells". He wrote that calling them stem cells was being used to suggest to patients that the cells would turn into new tissue in their bodies.5
Where they come from, and why it matters
MSCs from different sources are not interchangeable. The tissue they come from, the age of the donor and of the cells, and differences from one donor to another all vary between preparations.10 Two researchers write that there "may be very meaningful differences" in how MSCs behave depending on their tissue source, how they were grown, and how far they were expanded.12 Populations from different donors also differ in which genes they express.8
What researchers describe about how they act
MSCs were first thought to act by turning into other cells and replacing them. Researchers now describe their effects as mainly mediated by signalling molecules they release, known as paracrine factors, though actions of other kinds cannot be ruled out.10
In a 2011 proposal, Caplan and Correa suggested that MSCs sit around blood vessels, and that at a site of local injury they are released, become activated, and secrete molecules and regulate the local immune response; they likened them to a "drugstore".11 What MSCs release has been described as including cytokines, small molecules and extracellular vesicles.12,8
Few of them stay. Few transplanted MSCs settle and survive in the body, and fewer than one in a hundred may be detectable later.8 Given into a vein in mice, most are caught at once in the small blood vessels of the lungs.12 A study of human tissue after MSC infusions found that their fate is unclear, that donor DNA became less detectable with time, and described the cells as acting by "hit and run".13
Where the research stands
Studies of MSCs are hard to compare. When the definition was written, its authors noted that investigators used different methods to isolate, grow and characterise the cells, which made it "increasingly difficult" to compare one study with another.3 Standardisation between groups "is largely absent".10
Laboratory tests of potency, in the words of two researchers in the field, "at best" mirror "hypothesis-driven informed guesses".12 They describe most clinical trials as early-phase, and write that the results of later-stage trials have fallen short of the expectations raised by animal studies.12
The International Society for Stem Cell Research states that, for the vast majority of conditions for which "stem cell therapies" are marketed, there is not enough evidence that they are safe or that they work to justify routine or commercial use, and that the long-term safety of most cell-based interventions, MSCs included, "remains undetermined". It condemns giving unproven cell-based interventions outside clinical research, or medical innovation that follows its guidelines.2
The Food and Drug Administration warns of broad marketing of unapproved products, including stem cells, fat-derived cells, cord blood, Wharton's jelly and exosomes, and states that these products require FDA approval to be marketed. It has received reports of blindness, tumour formation and infections from their use.14
In December 2024 FDA approved its first product made from MSCs, for one condition in children.16 FDA states that unapproved products require its approval before they can be marketed.14
Whether any of this bears on your own health is a question for a physician, who can explain what is known, what is not, and what the risks are.
Glossary
- Stem cell
- A cell that can renew itself and develop into other cell types.1
- Pluripotent
- Able to give rise to all the tissues of an organism, other than those outside the embryo.2
- Multipotent
- Able to give rise to several cell types, but not to all of the cells of an organism.2
- Adult stem cell
- A stem cell found in a tissue or organ, which gives rise to the specialised cell types of that tissue or organ.1
- Mesenchymal stromal cell (MSC)
- A fibroblast-like cell that attaches to plastic in culture, whatever tissue it came from.4
- Stromal
- The term recommended for these cells unless evidence of stem cell activity has been shown.4,6
- CD markers (CD73, CD90, CD105)
- Proteins on a cell's surface used to identify it. An MSC must carry these three.3
- Paracrine factors
- Molecules a cell releases that affect other cells near and far.12
- Engraftment
- Transplanted cells settling and surviving in the body.8
- Potency assay
- A laboratory test meant to measure a preparation's biological activity.2,12
Sources
- National Institutes of Health. Stem Cell Basics. stemcells.nih.gov
- International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation (2021; updated 2025): glossary, and clinical translation of stem cell-based interventions. isscr.org
- Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–7. PubMed 16923606
- Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393–5. PubMed 16236628
- Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med 2017;6:1445–51. Open access (PMC5689741)
- Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 2019;21:1019–24. PubMed 31526643
- Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970;3:393–403. PubMed 5523063
- Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22. Open access (PMC6889290)
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–7. PubMed 10102814
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles 2019;8:1609206. Open access (PMC6493293)
- Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011;9:11–5. Open access (PMC3144500)
- Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 2018;22:824–33. Open access (PMC6434696)
- von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012;30:1575–8. PubMed 22553154
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. 2021, content current as of 8 April 2024. fda.gov
- Cancedda R, Mastrogiacomo M. The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood. Front Bioeng Biotechnol 2024;12:1414156. Open access (PMC11319133)
- U.S. Food and Drug Administration. Press announcement on the approval of Ryoncil (remestemcel-L-rknd), 18 December 2024. fda.gov